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Abstract
Background: People with hereditary spastic paraplegia (HSP) experience difficulties adapting their gait to meet
environmental demands, a skill required for safe and independent ambulation. Gait adaptability training is possible
on the C-Mill, a treadmill equipped with augmented reality, enabling visual projections to serve as stepping targets
or obstacles. It is unknown whether gait adaptability can be trained in people with HSP.
Aim: The aim of Move-HSP is to study the effects of ten 1-h sessions of C-Mill training, compared with usual care,
on gait adaptability in people with pure HSP. In addition, this study aims to identify key determinants of C-Mill
training efficacy in people with pure HSP.
Method: Move-HSP is a 5-week, two-armed, open-label randomized controlled trial with a cross-over design for the
control group. Thirty-six participants with pure HSP will be included. After signing informed consent, participants
are randomized (1:1) to intervention or control group. All participants register (near) falls for 15 weeks, followed by
the first assessment (week 16), and, thereafter, wear an Activ8 activity monitor for 7 days (week 16). The
intervention group receives 10 sessions of C-Mill training (twice per week, 1-h sessions; weeks 17–21), whereas
control group continues with usual care (weeks 17–21). Afterwards, both groups are re-assessed (week 22).
Subsequently, the intervention group enter follow-up, whereas control group receives 10 sessions of C-Mill training
(weeks 23–27), is re-assessed (week 28), and enters follow-up. During follow-up, both groups wear Activ8 activity
monitors for 7 days (intervention group: week 23, control group: week 29) and register (near) falls for 15 weeks
(intervention group: weeks 23–37, control group: weeks 29–43), before the final assessment (intervention group:
week 38, control group: week 44). The primary outcome is the obstacle subtask of the Emory Functional
Ambulation Profile. Secondary outcomes consist of clinical tests assessing balance and walking capacity, physical
activity, and fall monitoring.
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Discussion: Move-HSP will be the first RCT to assess the effects of C-Mill gait adaptability training in people with
pure HSP. It will provide proof of concept for the efficacy of gait adaptability training in people with pure HSP.
Trial registration: Clinicaltrials.gov NCT04180098. Registered on November 27, 2019.
Keywords: Hereditary spastic paraplegia, C-Mill, Gait adaptability, Rehabilitation
Background
Hereditary spastic paraplegia (HSP) is a heterogeneous
group of neurodegenerative disorders, caused by retro-
grade axonal degeneration of the corticospinal tracts,
fasciculus gracilis fibers, and to a lesser extent, the spi-
nocerebellar fibers [1–3]. Pure forms of HSP are clinic-
ally characterized by progressive spasticity, muscle
weakness, and reduced proprioception in the lower ex-
tremities, as well as difficulties in making rapid (alternat-
ing) leg movements [4–6]. Additional symptoms are
present in complex forms of HSP, including mental re-
tardation, epilepsy, ataxia, peripheral neuropathy, or
optic atrophy [1, 4, 7]. For people with pure HSP, gait
and balance impairments are among the most disabling
symptoms. They especially experience difficulties when
forced to adapt their gait to meet environmental de-
mands, hampering the ability to walk safely and inde-
pendently in the community [4, 8–11]. A recent study
reported that 57% of pure HSP patients fell at least twice
a year, and 73% experience fear of falling [11]. Incorpor-
ating gait adaptability training in rehabilitation programs
for people with pure HSP seems, therefore, logical and
potentially beneficial [4, 11, 12].
A limited number of task-specific gait interventions
have shown to improve walking capacity in people with
pure HSP. Twenty-five sessions of robot-assisted exo-
skeleton and overground walking improved walking vel-
ocity and balance capacity [13]. In addition, eighteen
sessions of robotic Lokomat training increased walking
speed, balance capacity, and quality of life [9]. Even
though these results are promising, the interventions
lacked tasks that promote gait adaptability. As a conse-
quence, it remains unknown whether people with pure
HSP will benefit from gait adaptability training [4]. Fur-
thermore, it is unclear how to tailor gait rehabilitation
programs to the individual patient with HSP as it is cur-
rently unknown which determinants can predict training
efficacy.
To fill this gap, Move-HSP is the first randomized
controlled trial to provide proof of concept for the effi-
cacy of gait adaptability training in people with pure
HSP. The training takes place in a safe environment on
the C-Mill, a treadmill providing augmented reality via
visual projections onto the treadmill. Participants will
train obstacle negotiation, precision stepping, and unex-
pected accelerations and decelerations. Its feasibility and
efficacy have been described in multiple neurological
populations, including patients with stroke [14], cerebel-
lar ataxia [15], and multiple sclerosis [16]. Currently, the
clinical experience with gait adaptability C-Mill training
for people with pure HSP is positive, but the scientific
evidence is lacking [4].
Objectives
This study aims to provide an essential step towards
evidence-based and individually tailored gait rehabilita-
tion in people with HSP. The objectives are twofold:
1. To study the effect of ten 1-h sessions of C-Mill
training on gait adaptability in people with pure
HSP.
2. To identify key determinants of C-Mill training effi-
cacy in people with pure HSP.
Methods/design
Regulation statement
Move-HSP will be conducted according to the principles
of the Declaration of Helsinki (64th WMA General As-
sembly, Fortaleza, Brazil, October 2013) and the Medical
Research Involving Human Subjects Act. The protocol is
written in accordance with the SPIRIT 2013 checklist.
Study design and setting
Move-HSP is a 5-week, single-center, two-armed, open-
label, randomized controlled trial (RCT), with a cross-over
design for the control group, as they receive the interven-
tion after a waiting list period. The study is conducted at
the Radboud University Medical Center (Radboudumc)
within the Center of Expertise for Parkinson & Movement
Disorders; Nijmegen, The Netherlands. C-Mill training can
be given at the Radboudumc (Nijmegen, The Netherlands),
Paramedisch centrum Rembrandt (Veenendaal, The
Netherlands), Stichting Tante Louise (Bergen op Zoom,
The Netherlands), and Fysiotherapie De Lindehoeve
(Voorschoten, The Netherlands). Other training locations
may be added while the study is ongoing, depending on the
success of participant inclusion.
Recruitment and selection
Participants will be recruited at the Center of Expertise for
Parkinson & Movement Disorders of the Radboudumc
(part of the European Reference Network for Rare
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Neurological Diseases (ERN-RND)). The treating phys-
ician informs the patient about Move-HSP and asks for
permission whether the investigator (LV) may contact the
patient. In addition, a request to participate will be sent to
members of the HSP patient organization “Spierziekten
Nederland”. Those who are interested can contact the in-
vestigator and will receive an information letter. After
2 weeks, the investigator (LV) will contact those who
expressed their interest and ask for their final decision. If
patients agree to participate, eligibility is checked. After
inclusion, participants can leave the study at any time
without consequences.
Eligibility
For inclusion, participants will have to meet the follow-
ing inclusion criteria:
 Diagnosis of pure HSP by a neurologist specialized
in inherited movement disorders. Diagnosis is based
on inheritance pattern and clinical examination, and
when available, molecular diagnosis.
 Age between 18 and 70 years old
 Ability to walk barefoot on a level ground for 50 m
without a walking aid (use of orthotic devices or
orthopedic shoes is allowed)
Participants will be excluded if they suffer from other
neurological, orthopedic, or psychiatric conditions, or if
patients underwent an HSP-related surgical procedure of
the lower extremities.
Group allocation and blinding
Participants will be allocated at random to the interven-
tion group or to the (waiting list) control group follow-
ing a 1:1 ratio. Randomization will be stratified based on
disease duration (2 categories: 0–15 years; > 15 years) in
blocks with a variable size (n = 4 or n = 6) to prevent an
uneven distribution between groups. To determine dis-
ease duration, participants are asked for the year of
symptom onset. Randomization will be performed in
CastorEDC, a web-based data management system for
academic studies (www.castoredc.com). Blinding of par-
ticipants is not possible, as participants will know
whether they receive C-Mill training or continue with
usual care. The primary investigator (LV) takes part in
the training sessions as a physical therapist and, there-
fore, cannot be blinded either.
Participant timeline
The outline of this study is shown in Fig. 1. Following
inclusion, participants are randomly allocated to either
the intervention group or the control group (waiting
list). During the first 15 weeks, all participants register
(near) falls in a digital fall calendar. Thereafter,
participants will have the first assessment at the move-
ment laboratory (Radboudumc; week 16). Following this
assessment, participants wear an Activ8 activity monitor
for seven consecutive days (week 16). Thereafter, the
control group enters a waiting period of 5 weeks (weeks
17–21), whereas the intervention group starts with
5 weeks of gait adaptability training on the C-Mill
(weeks 17–21). Each session lasts 1 h and takes place
twice per week. Subsequently, both groups are re-
assessed (week 22). Following this second assessment,
the intervention group enters the follow-up period,
whereas the control group wears the Activ8 activity
monitors for 7 days (week 22), starts 5 weeks of gait
Fig. 1 Flowchart of the study protocol
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adaptability training (weeks 23–27), has the third assess-
ment (week 28), and thereafter, enters the follow-up
period. During follow-up, both groups wear Activ8 activ-
ity monitors during the first week (intervention group:
week 23, control group: week 29) and, additionally,
register (near) falls for 15 weeks (intervention group:
weeks 23–37, control group: weeks 29–43). After follow-
up, participants have a final assessment in the movement
laboratory (intervention group: week 38, control group:
week 44).
During Move-HSP, all participants can continue their
usual care. For some participants, this may include local
intramuscular injections of botulinum toxin (BTX). To
limit the influence of BTX injections on the outcomes,
the scheduling of the assessments will consider the date
of the BTX injections. BTX injections induce an effect
on muscle spasticity approximately 2 weeks post-
injection. The maximum effect is reached around 6–8
weeks, after which it gradually subsides [17, 18]. Partici-
pants who receive BTX injections in the lower extrem-
ities will have the pre-intervention assessment 4 weeks
post-injection, and the post-intervention assessment
10 weeks post-injection. In addition, it will be monitored
whether the dosage of oral antispasmodic changes dur-
ing the trial.
Control group
The eighteen participants attributed to the control group
are asked to continue with their daily routine and usual
care during the 5 weeks on the waiting list. If therapy is
part of the usual care, participants are requested to con-
tinue with the same frequency and composition during
the waiting period.
Intervention: C-Mill training
Gait adaptability training takes place on the C-Mill
(Motek Medical, Culemborg, The Netherlands). The C-
Mill is a treadmill, providing augmented reality via visual
cues projected onto the treadmill. The projections are ei-
ther stepping targets or obstacles that challenge the par-
ticipants to adjust their steps accordingly. The training
sessions take place during five consecutive weeks, twice
per week during 60-min sessions. In total, participants
will train gait adaptability on the C-Mill for 10 h.
The C-Mill protocol is based on clinical experience
and finalized after a focus group discussion with expert
physical therapists. The training sessions are logged to
ensure compatibility and a consistent progression. Each
session starts with a 10-min warming-up, followed by
five training blocks (Fig. 2, video). Each training block
lasts approximately 8 min. Block A targets precision
stepping by practicing accurate foot placement on the
projected stepping tiles. Block B targets obstacle negoti-
ation by avoiding the projected obstacles. Block C elicits
changes in the direction of progression by using a variety
of slalom trajectories. Block D targets precision acceler-
ation and deceleration, as the participants must walk
within a projected square that moves forward and back-
ward on the treadmill. Block E challenges walking at dif-
ferent walking speeds. Block F is the endgame, a 5-min
track that combines several gait adaptability components
in an interactive way. All sessions end with a cooling-
down. To further promote the level of variability, each
training block consists of small components (i.e., for
block A: Stepping Tiles: belt speed will momentarily in-
crease; width between the stepping stones will moment-
arily decrease). In addition, different walking speeds are
used: 100% is the participant’s comfortable walking
speed on the treadmill. This will be determined during
the first training session. The belt speed will be manually
increased until the participant experiences it as comfort-
able. The therapist will then increase the belt speed with
0.3 m/s and slowly decrease the belt speed until the par-
ticipant again experiences it as comfortable. The average
of both speeds will be used to set the comfortable walk-
ing speed. Other percentages (e.g., 40%, 70%, 120%) are
derived from this reference speed. The C-Mill training
will be carried out by a physiotherapist with C-Mill cer-
tification. Progression over the training period is initi-
ated and controlled by this therapist and based on the
patient’s capacity and performance. It comprises of in-
creasing the level of task variability, increasing obstacle
size, and the addition of a dual task, for example the use
of the auditory Stroop task. During the Stroop task, par-
ticipants listen to an audiotape presenting a random se-
quence of the words “high” or “low”, expressed in either
a low-pitched voice or a high-pitched voice. They are
asked to respond aloud indicating the pitch of the word
(“high” or “low”), while ignoring the (randomly conflict-
ing) semantic meaning of the word.
Procedure and assessments
All outcome measurements will be collected during the
assessments at the movement laboratory (Table 1). The
intervention group is evaluated three times: pre C-Mill
training (week 16), post C-Mill training (week 22), and
at the end of the follow-up (week 38). The control group
is evaluated four times: pre waiting-list (week 16), post
waiting-list (week 22), post C-Mill training (week 28),
and at the end of the follow-up (week 44). The assess-
ments will follow a standardized protocol and are con-
ducted by the primary investigator (LV) who is trained to
perform the outcome measurements. As the primary in-
vestigator takes part in the training sessions, outcome as-
sessment cannot be blinded. During all assessments, the
use of orthotic devices and/or orthopedic footwear is
allowed depending on the task. No other (walking) aids
are allowed. If participants use any orthotic or orthopedic
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device during a task, this will be registered and kept con-
stant throughout the consecutive assessments.
Demographic and clinical assessments
The demographic and clinical assessments are collected
during the first assessment in the movement laboratory.
The demographic characteristics consist of age; sex;
height; weight; presence (or absence) of a genetic diag-
nosis and inheritance pattern; disease duration (i.e., the
number of years since symptom onset); regular use of
medication, orthopedic shoes or orthotic devices, or
other walking aids; presence and severity of visual defi-
cits; and number of falls in the preceding year.
Clinical assessments consist of the Spastic Paraplegia
Rating Scale (SPRS) to determine disease severity [19].
Bilateral muscle strength is scored with the Medical Re-
search Council (MRC) scale for hip adduction, abduc-
tion, flexion, and extension; knee flexion and extension;
and ankle plantar and dorsiflexion [4, 20, 21]. Bilateral
muscle tonus is scored with the Modified Ashworth
Scale (MAS) for the hip adductors (hip 70° flexed), knee
flexion and extension, and ankle plantar and dorsiflexion
with knee extended (gastrocnemius) and knee flexed (so-
leus) [22]. Vibration sense is evaluated using a tuning
fork on bilateral patella, lateral malleolus, and at the first
metatarsophalangeal joint. Trunk control is assessed
using the Trunk Control Measurement Scale (TCMS)
[23]. Lastly, coordination is examined via (i) toe tapping,
and (ii) leg agility [24].
Primary outcome
The primary outcome is gait adaptability as measured
with the obstacle subtask of the Emory Functional Am-
bulation Profile (E-FAP). Participants are asked to nego-
tiate a 10-m course in which two wooden blocks (100(l)
× 10(w) × 5(h) cm) and a bin are placed along the walk-
way. The instruction given is to complete the task as fast
as possible but keep your own safety in mind. The num-
ber of seconds needed to complete the task is registered.
A faster time score indicates better gait adaptability. The
obstacle subtask of the E-FAP has previously been used
as an outcome measure for gait adaptability in several
neurological populations [14, 15]. The full protocol is
available online and via Wolf et al. [25].
Fig. 2 Overview of the C-Mill training
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Table 1 Standard protocol items: Recommendations for interventional trials (SPIRIT) figure
Overview of enrollment, interventions, and assessments during the study protocol. Timepoints T1, T2, and T3 are applicable for participants in the intervention
group and usual care group. Timepoint Ts is only applicable for participants in the usual care group
NA not applicable
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Secondary outcomes
Secondary outcome measures comprise of the following
clinical tests:
– 10-Meter Walk Test (10MWT)
The 10MWT is a standardized and recommended
measurement of walking velocity. Participants walk 13 m
in a straight line, first three times at comfortable speed
and then three times as fast as possible. Participants
have 3 m to accelerate to the requested speed. When the
first foot crosses the 3-m line, the timer starts. The timer
stops when the first foot crosses the 13-m line. Like this,
the number of seconds it takes to walk 10 m is recorded
[26]. The test has been found reliable, valid, and sensi-
tive in neurological populations [26] and has been used
in people with HSP [9, 13, 27, 28].
– Mini Balance Evaluation Systems Test (miniBEST)
The mini-BEST is a 14-item, 3-point ordinal rating
scale (0–2 points) to evaluate balance capacity in 4 sub-
categories: anticipatory postural control, reactive pos-
tural control, sensory orientation, and gait stability. The
attainable sum scores range from 0 to 28 points, a higher
score indicating better balance capacity. Participants per-
form the test barefoot. The full protocol is available on-
line and has been described by Franchignoni et al. [29].
The mini-BEST is often used in neurological popula-
tions; has been found valid, reliable, and responsive [30–
32]; and has been recommended for use in people with
HSP [4].
– Physical activity levels during daily life
Physical activity during daily life will be registered via
the Activ8 Physical Activity Monitor (Activ8, Remedy
Distribution Ltd., Valkenswaard, The Netherlands). The
Activ8 monitor is a small (30 × 32 × 10mm) and light-
weight device with three axial accelerometers. It registers
body positions (non-wear of the Activ8/lying, sitting,
and standing) and activities (walking, running, cycling)
[33]. The Activ8 is placed by the primary researcher
using Tegaderm™ tape on the right upper thigh of the
participants. Interval for data sampling will be set to one
measurement per 15 s. Collected measures consist of
total time spent walking (minutes) and total time spent
active (i.e., minutes classified as walking, running or
cycling).
– Activities-specific Balance Confidence scale (ABC)
Balance confidence will be measured using the ABC.
The questionnaire describes sixteen indoor and outdoor
situations. Participants are asked to express their confi-
dence in safely executing the proposed situations with-
out falling. Scores range from 0 to 100, a higher score
indicating more confidence. The ABC has been used to
assess balance confidence in people with HSP [27, 34].
The full questionnaire is available via Powell et al. [35].
– Fall calendar
The fall calendar is used to monitor falls and near falls
and is self-reported by the participants during a 15-week
period. The World Health Organization defined a fall as
“an event which results in a person coming to rest inad-
vertently on the ground or other lower level.” A near fall
is defined as “a stumble event or loss of balance that
would result in a fall if sufficient recovery mechanisms
were not activated” [36]. In addition, participants register
incidents where a fall was likely to happen, but was
averted through the action of another person. When a
(near) fall occurs, the participant is asked to report a
short description of the event, the environment (indoor/
outdoor, illuminated/dark space, and surface (e.g., tiles,
carpet, forest)), and lastly, whether the (near) fall re-
sulted in any injuries. To meet participants’ preference,
calendars can be filled in digitally or on paper. Every
other week, participants are reminded of the fall calen-
dar via a phone call from the primary investigator (LV).
– Walking Adaptability Ladder Test (WALT)
The Walking Adaptability Ladder Test (WALT) is a
test to measure step precision. A standardized ladder is
placed on the floor. It consists of 17 rectangular stepping
targets that gradually decrease 2 cm in length (range
64–32 cm). Participants start stepping in the largest tar-
get and walk as fast as possible to the other side, turn
and hit the targets in reverse order while avoiding the
ladder rungs. The instructions are to perform the test as
fast as possible, but try to prevent foot placement errors.
The test is timed: a faster time is indicative of better
stepping precision. Participants perform the test four
times, first twice with one foot per target and, thereafter,
twice with both feet in one target. A time penalty of 0.5
s is added each time a participant makes a foot place-
ment mistake.
– Spatio-temporal gait parameters
Spatio-temporal gait parameters are collected with a
3D full body gait analysis using Vicon (Vicon© Motion
systems Ltd.) at the movement laboratory of the
Radboudumc, Nijmegen. Retroreflective markers are
placed on anatomical landmarks according to the stand-
ard Plug-in Gait marker model for upper and lower
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body. In addition, participants will wear accelerometers
on their lateral heels, as the higher measuring frequency
will enable a more accurate gait event detection. Partici-
pants will walk two bouts of 3 min over an 8-m walkway.
The following spatio-temporal parameters will be re-
trieved: step length (cm), step width (cm), step time (s),
walking speed (m/s), stride time (s), stride length (cm),
and cadence (steps/min).
Assessment of therapy adherence and co-interventions
To support adherence to the protocol, participants will
be in direct contact with the primary investigator (LV)
by telephone every other week. This enables the investi-
gator to verbally confirm assessments and training dates,
check adherence to the fall calendar, and quickly address
and resolve questions and possible problems that may
interfere with continuation of the protocol. In addition,
participants are offered flexible time slots for the assess-
ments and training sessions. Assessment of adherence to
the C-Mill protocol is possible as therapists will log the
performed C-Mill trainings. In case of an unexpected
cancelation, the reason will be registered, and the missed
training can be compensated in the next week. When
multiple consecutive training sessions cannot proceed, a
pragmatic solution is sought so that the participant is
able to complete the protocol.
In addition, assessment of co-intervention will take
place during the assessments. Participants are asked to
self-report in a survey what type of co-intervention they
received (e.g., physical therapy, occupation therapy).
Sample size
Sample size calculation is based on previous studies
assessing effectiveness of C-Mill training on the obstacle
subtask of the E-FAP scores in neurological populations
[14, 15]. A total of 32 participants is sufficient to demon-
strate an improvement on the E-FAP score of 1.75 s
(SD = 2.0 s, α = 0.05, β = 0.2). Considering a 10% attrition
rate, 36 participants will be included.
Statistical analysis
The effect of gait adaptability training on primary and sec-
ondary outcomes will be tested using ANCOVA. Post-
intervention measurements will be used as dependent var-
iables with pre-intervention measurements as the covari-
ate. Group (C-Mill versus waiting list) is used as an
independent between-subjects factors. The retention of
gait adaptability training will be tested by merging both
groups and using a repeated measures ANOVA with time
as a within-subjects factor (C-Mill group: assessments 1,
2, and 3; waiting list: assessments 2, 3, and 4). Post hoc
tests will be performed in the case of significant main or
interaction effects, using paired t tests. Fall rates will be
processed descriptively. Depending on the distribution of
the data, the rate of near falls may be analyzed using Wil-
coxon signed rank test. In addition, to determine key de-
terminants of C-Mill training efficacy, a stepwise linear
regression analysis will be performed with training-
induced change in gait adaptability (relative change of the
obstacle subtask of the E-FAP) as the dependent variable.
Univariate analyses will be performed to select the best
factors from the available demographic and clinical
characteristics.
Discussion
Limitations in walking capacity are among the most
disabling symptoms in people with hereditary spastic
paraplegia (HSP). A handful of studies aimed to im-
prove walking capacity in people with HSP [9, 13,
37], but these studies did not include context-specific
exercises aimed at gait adaptability. Gait adaptability
has been successfully trained in several neurological
populations using augmented reality on the C-Mill
[14, 15], but so far, this has never been done in
people with HSP.
Move-HSP is a two-armed, open-label randomized
controlled trial that will be the first study to assess the
effects of gait adaptability training in people with pure
HSP. Participants in the intervention group receive 10 h
(1-h sessions; twice per week) of protocolled C-Mill
training, whereas the control group continues with treat-
ment as usual (waiting list). After 5 weeks on the waiting
list, the control group will cross over and follow gait-
adaptability training. The primary outcome is gait adapt-
ability assessed with the obstacle subtask of the E-FAP.
Secondary outcomes focus on several aspects of balance
and gait capacity. Mildly to moderately affected people
with pure HSP that fit the a-priori established eligibility
criteria will be included. There are no restrictions re-
garding sex, symptom duration, or use of orthotic/ortho-
pedic devices in order to represent the clinical
heterogeneity characteristic of people with pure HSP.
Yet, to provide proof op principle and limit the influence
of impaired cognitive capacity, people with complex
forms of HSP are excluded.
Move-HSP aims to make a step towards evidence-
based and individually tailored gait rehabilitation pro-
grams for people with HSP. It will reveal whether
context-specific training is an effective tool for improv-
ing gait adaptability in people with pure HSP. If the C-
Mill intervention results in improved walking adaptabil-
ity, it may be beneficial to implement this type of train-
ing on a regular basis in the rehabilitation of people with
HSP. In addition, knowledge of the key determinants of
training efficacy will help to optimize the selection of
subjects with HSP that are most responsive to gait
adaptability training.
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Trial status
Participant recruitment has started in November 2019
and is currently ongoing. So far, no assessments in the
movement laboratory have yet been conducted. It was
originally anticipated that a total of 10 months would be
needed to complete the recruitment and 24months to
complete the entire protocol, but the current SARS-
CoV-2 pandemic will undoubtedly lengthen these pe-
riods to an unforeseeable extent. This study protocol is
based on protocol version 5, dated October 31, 2019. An
amendment to add training locations was approved on
February 18, 2020.
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Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04932-9.
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15 years in accordance with Dutch national legislation.
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The results will be presented at (inter) national conferences, published in
(inter) national scientific peer-reviewed journals, and included in the doctoral
dissertation of LV.
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